GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...
GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...
GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Among the companies with reports and trading updates today are Next, GSK, Aston Martin Lagonda and CAB Payments. Read the 30 October Business Live blog below. (PA) - Time Out Group has sharply cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback